HealthcareHealthcare ServicesHealthcare Service Provider

Thyrocare Technologies Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 82 filings·Updated 19 Aug 2026
Showing 10 of 82 filings.
19 Aug 20262 filings
Others

Please find enclosed the Intimation regarding complete discharge and release of Transaction Documents pursuant to full redemption and repayment of Non-Convertible Debentures by API Holdings Limited

Filed 21:05View Source
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Release of pledge on 7,94,69,696 Thyrocare shares by Catalyst Trusteeship for API Holdings debenture holders

Pledge release details

  • Acquirer: Catalyst Trusteeship Limited, Debenture Trustee for API Holdings Limited; not promoter.
  • Transaction: Release of pledge on 7,94,69,696 Thyrocare equity shares.
  • Pre-transaction encumbrance: 7,94,69,696 shares; voting rights Nil.
  • Date of release: August 17, 2026.
  • Post-transaction holding: no shares or encumbrances held by acquirer.
  • Before/after equity capital: 15,91,65,315 shares.
  • Post-diluted capital: 15,96,30,252 shares.
  • Mode: Release of pledge upon full repayment and redemption of NCDs.
Filed 11:00View Source
18 Aug 20267 filings
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Pledge release on 1.75 crore Thyrocare shares by Docon (promoter) on Aug 11, 2026

Pledge release details

  • Target Company: Thyrocare Technologies Limited.
  • Disclosing Party: Docon Technologies Private Limited (promoter) with API Holdings Limited as PAC.
  • Transaction type: Release of pledge on 1,75,00,000 Thyrocare equity shares.
  • Pre-transaction encumbrance: 9,69,69,696 encumbered shares (60.92%), voting rights NIL.
  • Post-transaction holdings: voting rights 1,75,00,000; encumbered shares 7,94,69,696 (49.93%).
  • Date: August 11, 2026 (Release of Pledge).
  • Equity capital before: 15,91,65,315 shares; after: 15,91,65,315 shares.
  • Total diluted capital after: 15,96,30,252 shares.
Filed 11:18View Source
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Promoter Docon Technologies releases pledge on Thyrocare shares after API Holdings debt repayment

Key details

  • Target Company: Thyrocare Technologies Limited.
  • Disclosing Party: Docon Technologies Private Limited (Promoter).
  • Transaction Type: Release of encumbrance on promoter shares.
  • Pre-Transaction pledged shares: 7,94,69,696.
  • Transaction Details: Pledge released on 7,94,69,696 equity shares; mode: encumbrance release; debt repayment by API Holdings.
  • Post-Transaction encumbrance: 0; promoter's shares now free from pledge.
  • Date of transaction: not disclosed.
Filed 11:15View Source
Insider Trading / SASTDisclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

Release of promoter share pledge on Thyrocare shares following NCD redemption; no change in holding.

Encumbrance release details

  • Target company: Thyrocare Technologies Limited.
  • Encumbrance type: Pledge on Thyrocare shares.
  • Encumbered shares: 7,94,69,696.
  • Promoter: Docon Technologies Private Limited.
  • PACs with promoter: API Holdings Limited.
  • Favouring entity: Catalyst Trusteeship Limited (Debenture Trustee).
  • Reason for encumbrance: security for NCDs issued by API Holdings Limited.
  • NCD principal amount: INR 10,500 million.
  • Date of release: August 17, 2026.
  • Pledge release: August 17, 2026; NCDs redeemed August 14, 2026.
  • Post-event holding: 8,12,00,000 fully released Thyrocare equity shares.
  • No change in Docon's Thyrocare shareholding.
Filed 11:14View Source
Insider Trading / SASTDisclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

Release of pledge on Thyrocare promoter shares after NCD redemption; promoter stake remains unencumbered

Encumbrance release details

  • Target: Thyrocare Technologies Limited.
  • Type of encumbrance: pledge on promoter shares.
  • Shares encumbered before: 7,94,69,696 (≈51.0%); after: 0 encumbrance.
  • Promoter: Docon Technologies Private Limited.
  • Favour: Catalyst Trusteeship Limited (Debenture Trustee).
  • Reason: security for NCDs issued by API Holdings Limited.
  • NCD facility size: INR 10,500 million; fully redeemed.
  • Promoter holding: 8,12,00,000 shares (51.02%); encumbrance released; none remaining.
  • Date: August 17, 2026.
  • No change in control; no future encumbrance undertakings disclosed.
Filed 11:13View Source
Insider Trading / SASTDisclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

HSBC Mutual Fund increases Thyrocare stake to 6.63% voting rights after 1.88% open market purchase

Transaction details

  • Target company: Thyrocare Technologies Limited.
  • Acquirer: HSBC Mutual Fund; no PAC disclosed.
  • Acquirer is not part of promoter/promoter group.
  • Stock exchanges: BSE Limited; NSE.
  • Pre-acquisition holding: 75,57,935 shares (4.75% voting rights).
  • Acquired voting rights: 29,99,731 shares (1.88%).
  • Post-acquisition holding: 1,05,57,666 shares (6.63%).
  • Mode of acquisition: Shares Purchased.
  • Date of acquisition: August 13, 2026.
  • Equity share capital before acquisition: 15,91,65,315 shares.
  • Equity share capital after acquisition: 15,91,65,315 shares.
  • Total diluted share/voting capital after acquisition: 29,99,731.
Filed 10:58View Source
Insider Trading / SASTDisclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

Release of pledge on Thyrocare promoter shares by Docon in favor of Catalyst Trusteeship

Encumbrance release details

  • Target company: Thyrocare Technologies Limited.
  • Encumbrance: Release of pledge on 1,75,00,000 Thyrocare equity shares.
  • Promoter: Docon Technologies Private Limited; PAC: API Holdings Limited.
  • Before release: 9,69,69,696 shares encumbered (60.92%).
  • After release: 7,94,69,696 shares encumbered (49.93%).
  • Beneficiary: Catalyst Trusteeship Limited, as Debenture Trustee.
  • Reason: security for NCDs issued by API Holdings Limited.
  • Outstanding NCDs: INR 10,500 million.
  • Date of pledge release: August 11, 2026.
  • Post-event promoter-encumbered share percentage: 49.93%.
Filed 10:50View Source
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Docon promoter releases pledge on Thyrocare shares after full NCD repayment

Key details

  • Target Company: Thyrocare Technologies Limited.
  • Disclosing Party: Docon Technologies Private Limited (Promoter) and API Holdings Limited (PAC).
  • Transaction Type: Release of pledge on Thyrocare shares.
  • Pre-Transaction Holding: Voting rights 17,30,304; encumbrance 7,94,69,696; total 8,12,00,000 (51.02%).
  • Transaction Details: Release of pledge on 7,94,69,696 shares; mode: pledge release; date: Aug 17, 2026.
  • Post-Transaction Holding: Voting rights 8,12,00,000 (51.02%); encumbrance: Nil; diluted capital 15,96,30,252.
  • Date of Transaction: August 17, 2026.
  • Share Capital Context: Before/after equity capital 15,91,65,315; diluted post-transaction 15,96,30,252.
Filed 10:06View Source
17 Aug 20261 filing
Insider Trading / SASTDisclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

Release of pledge on Thyrocare promoter shares after API Holdings' NCD redemption

Event details

  • Company: Thyrocare Technologies Limited.
  • Encumbrance type: pledge over promoter shares.
  • Shares encumbered before release: 7,94,69,696 Thyrocare shares.
  • Post-event status: pledge fully released; no outstanding promoter encumbrance.
  • Promoter: Docon Technologies Private Limited; PAC: API Holdings Limited.
  • Encumbrance in favor of: Catalyst Trusteeship Limited (Debenture Trustee).
  • Reason: to secure API Holdings Limited's NCD obligations.
  • NCDs: outstanding INR 10,500 million; fully redeemed Aug 14, 2026.
  • Date of pledge release: Aug 17, 2026.
  • Impact: promoter holding unchanged; no encumbrance remains on Thyrocare shares.
Filed 14:56View Source
Showing 10 of 82 filings